Loading data for KOD — first visit, this takes a few seconds.
Kodiak Sciences Inc. (KOD)
NasdaqGM: KOD
· Real-Time Price · USD
39.33
-0.13 (-0.33%)
At close: Aug 27, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Kodiak Sciences Inc. (KOD) Stock Price, Analysis & Data
-0.33% (1D)
| Bid | 30.95 |
| Market Cap | 2.43B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -241.99M |
| 2.21 | |
| -4.19 | |
| n/a | |
| -10.33 | |
| P/B (ttm) | 39.72 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 55.16 |
| Volume | 296,797 |
| Avg. Volume (20D) | 702,425 |
| Open | 39.94 |
| Previous Close | 39.46 |
| Day's Range | 38.40 - 40.03 |
| 52-Week Range | 8.29 - 47.84 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabet...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 4, 2018
Employees 141
Stock Exchange NasdaqGM
Ticker Symbol KOD
Website https://kodiak.com
Financial Performance
In 2025, Kodiak Sciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -229.97M, an increase of 30.51%.
Financial StatementsEarnings Surprise
Kodiak Sciences has released their quarterly earnings on Aug 13, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.05 misses estimates by -0.09, with -1.94% YoY decline.
Kodiak Sciences Inc. is scheduled to release its earnings on Nov 12, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2